A myelodysplastic neoplasm with del(5q) treated with luspatercept uncovers unexplored mechanisms of action for the drug

医学 全血细胞减少症 来那度胺 骨髓增生异常综合症 菲格拉斯汀 中性粒细胞减少症 中止 无效红细胞生成 内科学 国际预后积分系统 骨髓 沙利度胺 贫血 阿扎胞苷 骨髓增生性肿瘤 外科 耐受性 红细胞生成 胃肠病学 骨髓纤维化 不利影响 化疗 多发性骨髓瘤 生物化学 基因 DNA甲基化 化学 基因表达
作者
Iraklis Patsialos,Christina‐Nefeli Kontandreopoulou,Dimitra Vlachopoulou,Christos Stafylidis,Stavroula Syriopoulou,Fani Kalala,Amalia Anastasopoulou,Marina Mantzourani,Panagiotis Diamantopoulos
出处
期刊:British Journal of Haematology [Wiley]
标识
DOI:10.1111/bjh.19708
摘要

We would like to report the unique case of a 79-year-old man with myelodysplastic syndrome (MDS) with low blasts and isolated 5q deletion (Khoury et al., 2022)1 who was effectively treated with luspatercept. During the previous 10 months, he had received care at another healthcare facility with epoetin alpha and filgrastim, followed by five cycles of azacitidine, with no response, and he presented to us with severe pancytopenia. His past medical history was unremarkable except for heterozygous sickle cell disease. His bone marrow showed dyserythropoiesis, hypolobulated megakaryocytes and micromegakaryocytes, 2% myeloblasts, with no ring-shaped sideroblasts, with cytogenetics being 45,X,-Y,del(5)(q12q33)[12]/45,X,-Y[8] and no genomic alterations by next-generation sequencing. The revised International Prognostic Scoring System score was 3.5 (intermediate risk). The patient was started on lenalidomide at 10 mg qd for 21 days in 28-day cycles, along with deferasirox and filgrastim but due to ongoing grade 4 anaemia, neutropenia and thrombocytopenia, the lenalidomide dose was reduced and, finally, discontinued after 6 months, while he was heavily transfusion-dependent (Figure 1A). He was then started on off-label luspatercept at 1 mg/kg SC, increased after two 21-day cycles to 1.33 mg/kg subcutaneously. After five doses with no need to titrate to the maximum dose, treatment was discontinued due to a normal haemoglobin level and increased platelet and neutrophil counts (Figure 1B). The patient continued to increase his blood counts even off treatment. Fourteen months after luspatercept discontinuation, his marrow showed no dyserythropoiesis, normally maturing megakaryocytes and granulocytes, and blasts <1%, with a normal karyotype (45,X,-Y[30]), requiring no treatment, except for deferasirox (Figure 1C). Myelodysplastic syndrome with del(5q) constitutes approximately 5% of MDS and typically affects women, presenting with erythropoietin-refractory macrocytic anaemia, dyserythropoiesis, normal or elevated PLT counts, giant platelets, hypolobulated micromegakaryocytes and variable neutropenia. It is characterized by prolonged survival and a lower progression rate to acute myelogenous leukaemia,2 as well as high erythroid responses to lenalidomide,3 with frequent dose adjustments due to haematological toxicity.4 Luspatercept is an erythroid maturation agent that enhances late-stage erythropoiesis, reducing aberrant Smad2/3 signalling by binding transforming growth factor beta (TGFβ) superfamily ligands.5 It has been approved for anaemia in erythropoietin-naïve, transfusion-dependent adults with lower risk MDS, but it has not been tested in del(5q) patients.6 Regarding our patient, a trial of luspatercept was deemed well justified, since he did not benefit from a 6-month course of lenalidomide and experienced worsening pancytopenia, requiring regular red blood cell transfusions. In conclusion, the above preclinical data on the complex actions of the SMAD–TGFβ pathway on different blood cells as well as the limited clinical data on the effects of luspatercept on inflammatory pathways provide indirect clues that luspatercept's mechanism of action is more complex than a simple enhancement of late-stage erythropoiesis, spanning different haematopoietic cells and pathways that may affect haematopoiesis and inflammation, as a whole. Nevertheless, this data are still inadequate to guide further investigations, outside the context of clinical trials. I.P. performed data analysis and interpretation and wrote the main text. C.-N.K. contributed to drafting and writing the text. D.V., C.S, F.K. and A.A contributed to drafting sections of the document. M.M. reviewed and approved the final version of the document. P.D. coordinated the report, performed abstract and full-text screening, reviewed and revised the main document. This report did not receive any specific grant from funding agencies. None of the authors have a conflict of interest to disclosure. Not applicable to this study. Written informed consent was obtained from the patient for publication of this letter to the editor, a copy of which is available for review by the Senior Editor of British Journal of Haematology. All procedures followed were in accordance with the Helsinki Declaration. In the presence report since there are no photographs of any part of the body that could identify the patient, the IC will not be uploaded. Data that support the findings of this report are available from Prof. Panagiotis Diamantopoulos upon reasonable request. Due to clinical and ethical restrictions, patient identifiable information are not publicly available.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包应助醒醒采纳,获得10
2秒前
xingsixs发布了新的文献求助10
2秒前
CT发布了新的文献求助10
2秒前
城市猎人完成签到,获得积分10
5秒前
sci发布了新的文献求助10
5秒前
LeoYiS214完成签到,获得积分10
6秒前
二马三乡完成签到 ,获得积分10
9秒前
10秒前
木野狐发布了新的文献求助10
13秒前
喂喂完成签到 ,获得积分10
15秒前
16秒前
干净问筠完成签到,获得积分10
17秒前
kang发布了新的文献求助10
18秒前
19秒前
19秒前
荷子完成签到,获得积分20
21秒前
21秒前
21秒前
21秒前
23秒前
24秒前
ReBorn发布了新的文献求助10
24秒前
裴仰纳完成签到 ,获得积分10
25秒前
傲娇蓝血发布了新的文献求助30
25秒前
25秒前
撒西不理给撒西不理的求助进行了留言
26秒前
路灯下的小伙完成签到,获得积分10
26秒前
zym999999发布了新的文献求助10
29秒前
Jrssion发布了新的文献求助10
29秒前
夏惋清完成签到 ,获得积分0
30秒前
量子星尘发布了新的文献求助10
31秒前
ClaudiaCY发布了新的文献求助150
31秒前
kang完成签到,获得积分20
33秒前
天才臭屁星完成签到 ,获得积分10
34秒前
Ava应助粱涵易采纳,获得10
34秒前
Jasper应助Literaturecome采纳,获得10
35秒前
sci发布了新的文献求助10
35秒前
卜大大发布了新的文献求助10
36秒前
冷万天关注了科研通微信公众号
36秒前
seal发布了新的文献求助10
37秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3958068
求助须知:如何正确求助?哪些是违规求助? 3504219
关于积分的说明 11117555
捐赠科研通 3235582
什么是DOI,文献DOI怎么找? 1788351
邀请新用户注册赠送积分活动 871204
科研通“疑难数据库(出版商)”最低求助积分说明 802511